» Articles » PMID: 34357064

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

Overview
Journal Life (Basel)
Specialty Biology
Date 2021 Aug 6
PMID 34357064
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.

Citing Articles

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.

Wang J, Li Z, Yin H Ophthalmol Ther. 2024; 13(5):1103-1123.

PMID: 38498280 PMC: 11039591. DOI: 10.1007/s40123-024-00913-2.

References
1.
Arulananda S, Parakh S, Palmer J, Goodwin M, Andrews M, Cebon J . A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep (Hoboken). 2020; 2(4):e1183. PMC: 7941455. DOI: 10.1002/cnr2.1183. View

2.
Carvajal R, Sosman J, Quevedo J, Milhem M, Joshua A, Kudchadkar R . Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311(23):2397-405. PMC: 4249701. DOI: 10.1001/jama.2014.6096. View

3.
Walrand S, Chiesa C, Minguez Gabina P, Chouin N, Gear J, Stokke C . Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019; 30(12):2047-2048. DOI: 10.1016/j.jvir.2019.08.030. View

4.
Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, Lago-Baameiro N, Pardo M, Silva P . Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers (Basel). 2020; 12(9). PMC: 7565536. DOI: 10.3390/cancers12092557. View

5.
Tura A, Merz H, Reinsberg M, Luke M, Jager M, Grisanti S . Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res. 2016; 29(5):583-9. DOI: 10.1111/pcmr.12507. View